Get the Stockscreener App
13.12
2.67%
-0.37
Neogenomics Inc stock is traded at $13.12, with a volume of 223.49K.
It is down -2.67% in the last 24 hours and down -28.49% over the past month.
NeoGenomics Inc operates a network of cancer-focused genetic testing laboratories in the United States as well as a laboratory in Switzerland. The company operates into two segments namely Clinical Services and Advanced Diagnostics. It offers types of genetic and molecular testing services namely Cytogenetics, Fluorescence In-Situ Hybridization, Flow cytometry, Immunohistochemistry, Molecular testing, Pathology consultation. Advanced Diagnostics segment supports pharmaceutical firms in their drug development programs by supporting various clinical trials and research. For Clinical Services, Its specialized diagnostic services are performed based on an online test order or a written test requisition form. The company generates majority of its revenue from Clinical Services.
See More
Previous Close:
$13.49
Open:
$13.45
24h Volume:
223.49K
Relative Volume:
0.29
Market Cap:
$1.73B
Revenue:
$628.25M
Net Income/Loss:
$-78.55M
P/E Ratio:
-21.16
EPS:
-0.62
Net Cash Flow:
$-29.73M
1W Performance:
-8.18%
1M Performance:
-28.49%
6M Performance:
-17.16%
1Y Performance:
-6.58%
1-Day Range:
$13.03
$13.51
1-Week Range:
$13.03
$14.33
52-Week Range:
$12.12
$19.11
Neogenomics Inc Stock (NEO) Company Profile
Name
Neogenomics Inc
Sector
Industry
Phone
(239) 768-0600
Address
9490 NEOGENOMICS WAY, FORT MYERS, FL
Compare NEO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NEO
Neogenomics Inc
|
13.15 | 1.73B | 628.25M | -78.55M | -29.73M | -0.62 |
|
TMO
Thermo Fisher Scientific Inc
|
567.84 | 219.06B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
206.95 | 151.02B | 23.88B | 3.90B | 5.30B | 5.28 |
|
A
Agilent Technologies Inc
|
145.19 | 42.12B | 6.51B | 1.29B | 1.37B | 4.42 |
|
IDXX
Idexx Laboratories Inc
|
458.31 | 37.71B | 3.84B | 866.24M | 792.60M | 10.37 |
|
IQV
Iqvia Holdings Inc
|
207.38 | 36.97B | 15.32B | 1.41B | 1.96B | 7.62 |
Neogenomics Inc Stock (NEO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-13-25 | Downgrade | The Benchmark Company | Buy → Hold |
| Dec-10-24 | Initiated | Jefferies | Buy |
| May-01-24 | Resumed | Craig Hallum | Buy |
| Dec-29-23 | Reiterated | BTIG Research | Buy |
| Aug-21-23 | Upgrade | Stephens | Equal-Weight → Overweight |
| May-16-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| May-09-23 | Upgrade | BTIG Research | Neutral → Buy |
| Feb-24-23 | Upgrade | The Benchmark Company | Hold → Buy |
| Feb-01-23 | Upgrade | Needham | Hold → Buy |
| Aug-26-22 | Downgrade | The Benchmark Company | Buy → Hold |
| Aug-22-22 | Downgrade | Needham | Buy → Hold |
| Jun-03-22 | Initiated | Piper Sandler | Overweight |
| Mar-29-22 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-29-22 | Downgrade | Stephens | Overweight → Equal-Weight |
| Jan-18-22 | Resumed | Stephens | Overweight |
| Dec-16-21 | Initiated | Cowen | Outperform |
| Nov-05-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-14-21 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-03-21 | Initiated | Goldman | Buy |
| Feb-25-21 | Resumed | Needham | Buy |
| Feb-25-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jan-28-21 | Initiated | Truist | Buy |
| Dec-11-20 | Resumed | BTIG Research | Buy |
| Oct-28-20 | Reiterated | Needham | Buy |
| Sep-09-20 | Initiated | Morgan Stanley | Overweight |
| Aug-28-20 | Initiated | Guggenheim | Buy |
| Jul-29-20 | Reiterated | Needham | Buy |
| Jun-25-20 | Initiated | BofA/Merrill | Buy |
| Apr-21-20 | Resumed | Stephens | Overweight |
| Mar-02-20 | Resumed | Craig Hallum | Buy |
| Feb-28-20 | Upgrade | First Analysis Sec | Outperform → Strong Buy |
| Jan-23-20 | Downgrade | First Analysis Sec | Strong Buy → Outperform |
| Oct-30-19 | Reiterated | Needham | Buy |
| May-01-19 | Reiterated | Needham | Buy |
| Mar-29-19 | Reiterated | Needham | Buy |
| Jan-03-19 | Initiated | Needham | Buy |
| Oct-24-18 | Upgrade | First Analysis Sec | Outperform → Strong Buy |
| Aug-21-18 | Initiated | Leerink Partners | Outperform |
| May-02-18 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| Sep-11-17 | Downgrade | BTIG Research | Buy → Neutral |
| Aug-24-17 | Initiated | Gabelli & Co | Buy |
| Dec-15-16 | Initiated | Cantor Fitzgerald | Overweight |
View All
Neogenomics Inc Stock (NEO) Latest News
Oak Family Advisors LLC Has $224,000 Stake in NeoGenomics, Inc. (NASDAQ:NEO) - MarketBeat
Jennison Associates LLC Boosts Holdings in NeoGenomics, Inc. (NASDAQ:NEO) - MarketBeat
NeoGenomics to Participate in the BTIG Virtual Medtech, Digital Health, Life Science & Diagnostic Tools Conference - ACCESS Newswire
NeoGenomics (NASDAQ:NEO) Price Target Lowered to $18.00 at The Goldman Sachs Group - MarketBeat
The big haul - Financial Times
Pacific Biosciences of California Appoints NeoGenomics CEO to Board of Directors -January 30, 2025 at 10:30 am EST - Marketscreener.com
Strategic Power Move: NeoGenomics CEO Joins PacBio Board to Accelerate Clinical Market Push - StockTitan
PacBio adds NeoGenomics CEO to its board By Investing.com - Investing.com Canada
NeoGenomics Provides Update on MolDX Submission for CRC and RaDaR(TM) Commercial Launch - ACCESS Newswire
NeoGenomics to Report Fourth Quarter and Full Year 2024 Financial Results on February 18, 2025 - BioSpace
NeoGenomics, Inc. (NASDAQ:NEO) Shares Sold by Nisa Investment Advisors LLC - Defense World
NeoGenomics Sets Date for Major 2024 Financial Results RevealMark Your Calendar - StockTitan
NeoGenomics Reports Full Year Revenue of $484 Million and $126 Million for the Fourth Quarter of 2021 - ACCESS Newswire
NeoGenomics to Present at the 44th Annual Raymond James Institutional Investors Conference - ACCESS Newswire
Strong week for NeoGenomics (NASDAQ:NEO) shareholders doesn't alleviate pain of five-year loss - Yahoo Finance
NeoGenomics Announces Grand Opening of New Pharma Services Laboratory in Singapore - ACCESS Newswire
NeoGenomics To Virtually Participate In 17th Annual Craig-Hallum Institutional Investor Conference - ACCESS Newswire
NeoGenomics Reports Revenue Growth of 20% to Record $125 Million in the Third Quarter - ACCESS Newswire
Leerink Partnrs Predicts Reduced Earnings for NeoGenomics - Defense World
NeoGenomics Expands NGS Portfolio with Launch of Neo Comprehensive(TM)Solid Tumor CGP and Neo Comprehensive(TM)Myeloid Disorders CGP - ACCESS Newswire
Leerink Partnrs Forecasts Reduced Earnings for NeoGenomics - MarketBeat
NeoGenomics, Inc. (NASDAQ:NEO) Receives $20.30 Average Price Target from Analysts - Defense World
Brokerages Set NeoGenomics, Inc. (NASDAQ:NEO) PT at $20.30 - MarketBeat
Benchmark retains Hold on Neogenomics stock, raises 2025 revenue forecast - MSN
NeoGenomics (NEO) Surges 9.1%: Is This an Indication of Further Gains? - MSN
Benchmark retains Hold on Neogenomics stock, raises 2025 revenue forecast By Investing.com - Investing.com Canada
Neogenomics stock sees solid support from Needham on updated guidance and expansion plans - Investing.com Canada
NeoGenomics stock rises on upbeat 2025 financial outlook By Investing.com - Investing.com Australia
NeoGenomics Is On The Upswing, Reversing A CEO-Tied Sell-Off, On Bullish Long-Term Guidance - Yahoo! Voices
NEONeoGenomics, Inc. Latest Stock News & Market Updates - StockTitan
5 Analysts Assess NeoGenomics: What You Need To Know - Benzinga
NeoGenomics rises on upbeat sales outlook for 2025 - MSN
NeoGenomics (NASDAQ:NEO) Shares Gap UpStill a Buy? - MarketBeat
NeoGenomics stock rises on upbeat 2025 financial outlook - Investing.com
Cutting-Edge Cancer Therapies Lead the Way into a Transformative Year - Benzinga
NeoGenomics Announces Executive Bonuses and Revenue Growth - TipRanks
NeoGenomics Provides 2025 Financial Guidance and Updates Long-Range Financial Plan - The Bakersfield Californian
Adaptive, NeoGenomics partner to expand access to disease monitoring - MSN
Adaptive Biotechnologies and NeoGenomics Partner to Expand - GlobeNewswire
Adaptive Biotechnologies and NeoGenomics partner to expand access to disease monitoring for blood cancer patients - Seeking Alpha
Adaptive Biotechnologies and NeoGenomics Partner to Expand Access to Personalized Disease Monitoring for Blood Cancer Patients - The Manila Times
Adaptive Biotech Partners with NeoGenomics to Transform Blood Cancer Testing with clonoSEQ - StockTitan
What You Can Learn From NeoGenomics, Inc.'s (NASDAQ:NEO) P/S After Its 29% Share Price Crash - Simply Wall St
NeoGenomics (NASDAQ:NEO) Sets New 52-Week LowWhat's Next? - MarketBeat
NeoGenomics Inc (NEO) Trading Down 14.52% on Jan 13 - GuruFocus.com
NeoGenomics (NASDAQ:NEO) Trading Down 8%Here's What Happened - MarketBeat
NeoGenomics CEO Chris Smith to retire - MSN
Neogenomics Inc Stock (NEO) Financials Data
Revenue
Net Income
Cash Flow
EPS
8.26%
1.49%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):